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Abstract The optimum range of pulse oximeter oxygen sat-
uration (SpO2) for preterm infants remains controversial.
Between November 2015 and February 2016, we conducted
a web-based survey aimed to investigate the current and for-
mer practices on SpO2 targets in European neonatal intensive
care units (NICUs). We obtained valid responses from 193
NICUs, treating 8590 newborns ≤28 weeks per year, across
27 countries. Forty different saturation ranges were reported,
ranging from 82–93 to 94–99%. The most frequently utilized
SpO2 ranges were 90–95% (28%), 88–95% (12%), 90–94%
(5%), and 91–95% (5%). A total of 156 NICUs (81%)
changed their SpO2 limits over the last 10 years. The most
frequently reported former limits were 88–92% (18%), 85–
95% (9%), 88–93 (7%), and 85–92% (6%). The NICUs that
increased their SpO2 ranges expected to obtain a reduction in
mortality. A 54% of the NICUs found the scientific evidence
supporting their SpO2 targeting policy strong or very strong.
Conclusion: We detected a high degree of heterogeneity in
pulse oximeter SpO2 target limits across European NICUs.
The currently used limits are 3 to 5% higher than the former
limits, and the most extreme limits, such as lower below 85%
or upper above 96%, have almost been abandoned.
What is Known:
• For preterm infants requiring supplemental oxygen, the optimum range
of pulse oximeter oxygen saturation (SpO2) to minimize organ damage,
without causing hypoxic injury, remains controversial.
What is New:
• This survey highlights the lack of consensus regarding SpO2 target
limits for preterm infants among European neonatal intensive care units
(NICUs). We detected 40 different SpO2 ranges, and even the most
frequently reported range (i.e., 90–95%) was used in only 28% of the
193 respondent NICUs.
• A total of 156 NICUs (81%) changed their SpO2 limits over the last
10 years. The currently used limits are 3 to 5% higher than the former
limits, and the most extreme limits, such as lower below 85% or upper
above 96%, have almost been abandoned.
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Introduction
Oxygen is one of the most widely used drugs in the care of
(very) preterm infants, and arterial oxygen saturation mea-
sured by pulse oximetry (SpO2) is the standard, noninvasive,
continuous method used to guide oxygen therapy [6, 17, 18].
However, for preterm infants requiring supplemental oxygen,
the optimum range of SpO2 to minimize organ damage, with-
out causing hypoxic injury, remains controversial [9, 10].
Between 2005 and 2007, five randomized trials, known col-
lectively as the Neonatal Oxygen Prospective Meta-analysis
(NeOProM) collaboration, were designed to compare the ef-
fects of a lower SpO2 target range (85 to 89%) vs. a higher
target range (91 to 95%) in preterm infants (<28 weeks) [1,
11]. Combined, these trials suggest that, after postnatal stabi-
lization, the preterm babies assigned to the lower SpO2 target
range intention to treat may have increased mortality and nec-
rotizing enterocolitis (NEC), while keeping them in the higher
SpO2 range may increase the risk of retinopathy of prematu-
rity (ROP) [11, 18]. Nevertheless, several neonatologists have
raised concerns about potential drawbacks of high SpO2 tar-
gets and underlined the high degree of conflicting results of
the NeOProM trials [2, 4, 7–10, 14]. Additionally, a system-
atic review and meta-analysis using GRADE criteria conclud-
ed that although infants cared for with a higher SpO2 target
had significantly lower mortality before hospital discharge,
the quality of evidence for this estimate of effect is low [5].
Therefore, in the present climate of uncertainty, one would
expect institutional variations on SpO2 targets.
The purpose of this web-based survey was to investigate
how SpO2 monitoring policies vary among NICUs in Europe
and if the target ranges have been changed in the last years.
We also surveyed the expectations of the neonatologists on the
effects of changes in SpO2 targets and their opinion on the
strength of the presently available evidence.
Methods
This study received approval from the institutional review
board of the Maastricht University Medical Center. Potential
responders were informed that participation in the survey was
voluntary and that completion of the questionnaire implied
consent to participate. European regions differ widely in
how they organized the care of preterm infants [16], and to
the best of our knowledge, an exhaustive list of European
NICUs does not exist [3]. Therefore, in order to obtain the
maximal number of responses, we contacted through email a
delegate of the national neonatology society of each of the
countries mentioned below (see BResults^), requesting them
to distribute a web-based survey among the NICUs of their
respective country. If no response was obtained after 2 weeks,
we contacted another neonatologist of the country. The survey
was open between October 2015 and February 2016. The
head of the NICU, or a delegated senior neonatologist, was
required to fill in the survey, which consisted of the following
10 questions:
1. Please indicate the hospital, city, and country where your
NICU is placed.
2. What is your professional position? (head of the NICU/
senior neonatologist)
3. In the last year, approximately how many infants born at
≤28 weeks gestation have been admitted in your NICU?
4. Does your NICU have a written unit policy or guideline
for the desired oxygen saturation range for infants born
at ≤28 weeks gestation who are receiving oxygen thera-
py? (Yes/No)
5. In your NICU, in what range do you try to maintain
oxygen saturations for infants born at ≤28 weeks gesta-
tion who are receiving oxygen therapy?
6. Has your NICU’s policy regarding oxygen saturation
targeting for infants born at ≤28 weeks gestation been
changed in the last 10 years? (Yes/No)
7. If your answer to question 6 was Byes^, when were the
last changes introduced?
8. If your answer to question 6 was Byes^, indicate the num-
bers that correspond to the former low and high limits of
the oxygen saturation range for a 7-day-old infant born at
≤28 weeks gestation receiving oxygen therapy.
9. If your answer to question 6 was Byes^, which of the
following outcomes do you expect to be reduced with
the new saturation targeting policy? (Outcomes were
mortality, NEC, bronchopulmonary dysplasia, patent
ductus arteriosus, ROP, intraventricular hemorrhage,
per ivent r icular leukomalacia , and impai red
neurodevelopment. Participants were asked to respond
through a scale with 1 indicating very improbable and 5
indicating very probable)
10. In your opinion, how strong is the scientific evidence
supporting the beneficial/harmful effects of the oxygen
saturation targeting policy that you are currently using in
your NICU for infants born at ≤28 weeks gestation? (scale
with 1 indicating very weak and 5 indicating very strong).
Only descriptive statistics were performed including fre-
quency counts, percentages, mean and standard deviation as
well as median and interquartile range (IQR) when
appropriate.
Results
We received 200 responses from European NICUs, of which
193 were valid for analysis. Due to the method of distribution
and the absence of an exhaustive list of European NICUs [3,
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16], it was not possible to obtain complete data on the number
of NICUs that received the survey. Some of the contacted
neonatologists distributed the survey in their country but did
not notify us of the number of NICUs that were contacted.
Therefore, a response rate could not be determined. The 193
respondent NICUs treated 8590 infants aged ≤28 weeks in the
last year (median 40, IQR 22–55). The distribution of re-
sponses per country was the following: Belgium 9, Bosnia
and Herzegovina 1, Bulgaria 1, Czech Republic 3, Denmark
3, Finland 3, France 15, Germany 25, Greece 4, Hungary 6,
Iceland 1, Ireland 3, Italy 16, Latvia 1, Norway 1, Portugal 4,
Poland 1, Russia 18, Serbia 3, Slovakia 3, Slovenia 1, Spain
27, Sweden 13, Switzerland 6, the Netherlands 9, Turkey 12,
and UK 3. No response was obtained from Austria, Cyprus,
Estonia, Georgia, Lithuania, Macedonia, Malta, Romania, and
Ukraine. The head of the NICU responded the survey in 70%
of the cases.
A total of 140 NICUs (73%) reported to have a written
policy or guideline on oxygen saturation limits. The limits
currently used in the 193 NICUs are depicted in Table 1.
Limits were combined in 40 different ranges. The four most
frequently used ranges were 90–95, 88–95, 90–94, and 91–
95% (Fig. 1). The distribution of the ranges across the coun-
tries with more than five respondents is shown in Table 2.
From the 193 respondent NICUs, 156 (81%) changed their
oxygen saturation limits in the last 10 years (9 changed less
than 1 year ago, 29 changed 1 year ago, 48 changed 2 years
ago, 24 changed 3 years ago, 13 changed 4 years ago, 16
changed 5 years ago, 16 changed more than 5 years ago, and
1 did not answer). The limits formerly used in these 156
NICUs are depicted in Table 1 and the ranges in Fig. 2.
Table 3 shows the direction of the changes in SpO2 ranges.
The expectations on the effect of the changes on outcome are
shown in Fig. 3. For analysis of this question, responses were
divided into three groups: (1) NICUs using a lower limit of
86–88% and an upper limit ≤94% (n = 22), (2) NICUs using a
range of 88–95% (n = 19), (3) NICUs using a lower limit of
90–91% and an upper limit of 95% (n = 55). The evidence
supporting the beneficial/harmful effects of their current satu-
ration targeting policy was considered strong or very strong by
54% of the respondents, neutral by 30%, and weak or very
weak by 15%. The consideration on the strength of the evi-
dence within the above three groups is depicted in Fig. 3d.
Discussion
This survey highlights the lack of consensus regarding SpO2
target limits for preterm infants among European neonatolo-
gists. We detected 40 different SpO2 ranges and even the most
frequently reported range (i.e., 90–95%) was used in only
28% of the respondent NICUs. The heterogeneity in SpO2
target ranges was also a general observation within countries,
since only in two cases (Turkey and Hungary) the same range
was used by more than 50% of the NICUs of the same coun-
try. A similar degree of variability in SpO2 targets has been
recently reported among the NICUs of the UK [12]. Although
the method used for the distribution of our survey does not
allow us to calculate a response rate, we obtained numerous
responses of the majority of European countries, including the
largest NICUs. Other surveys on European NICUs reported a
number of responses similar to the one obtained by us [3].
Therefore, we believe the present results are representative
of current management practices in Europe.
An 81% of the NICUs reported a recent change in their
policy of SpO2 target limit. Despite the variability, two
Table 1 Current and former SpO2 limits used in European NICUs for
infants of gestational age ≤28 weeks
Number of centers
Current (n = 193), n (%) Former (n = 156), n (%)
Lower limit
80 4 (2)
82 1 (1) 2 (1)
83 1 (1) 4 (2)
84 3 (2)
85 12 (8) 53 (27)
86 5 (3) 10 (5)
87 5 (3) 9 (5)
88 33 (21) 65 (34)
89 9 (6) 3 (2)
90 70 (45) 20 (10)
91 10 (6) 2 (1)
92 7 (5) 8 (4)
93 2 (1)






90 1 (1) 9 (5)
92 8 (5) 53 (27)
93 18 (12) 31 (16)
94 21 (14) 9 (5)
95 92 (60) 47 (24)
96 11 (7) 8 (4)
97 2 (1) 6 (3)
98 14 (7)
99 1 (1) 6 (3)
100 5 (3)
The former limits refer to the limits previously utilized by the 156 NICUs
that changed their limits in the last 10 years
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consequences of these changes can be identified. First, the
currently used limits are 3 to 5% higher than the former limits.
Consequently, it would be wise to scrutinize the incidence in
conditions associated with hyperoxia such as ROP in the com-
ing years. Second, the most extreme limits, such as lower
below 85% or upper above 96%, have almost been aban-
doned. Taken together, these changes may reflect the impact
of the evidence generated by the NeOProM trials on clinical
Table 2 Distribution of SpO2 targeting limit ranges per country




Most frequent ranges (%)
First Second Third
Spain (n = 27) 24 (89) 12 90–95 (44) 88–95 (15) 90–94 (7)
Germany (n = 25) 16 (64) 12 90–95 (20) 85–95 (16) 85–93 (12)
Russia (n = 18) 17 (94) 13 90–95 (28) 92–95 (11)
Italy (n = 16) 9 (56) 12 88–95 (19) 90–95 (13) 87–94 (13)
France (n = 15) 12 (80) 9 88–95 (33) 92–95 (13) 89–95 (13)
Sweden (n = 13) 10 (77) 6 90–94 (23) 90–95 (23) 91–95 (23)
Turkey (n = 12) 9 (75) 5 90–95 (67)
Netherlands (n = 9) 9 (100) 7 90–95 (22) 91–95 (22)
Belgium (n = 9) 7 (78) 8 88–95 (22)
Hungary (n = 6) 6 (100) 3 90–95 (67)
Switzerland (n = 6) 4 (67) 5 85–92 (33)






















































Fig. 1 Current SpO2 ranges used in 193 European NICUs. Results are
expressed as n (%). The number in italic indicates the number of NICUs
having the same range over the last 10 years. For clarity, ranges reported
by only one or twoNICUs are not shown in the figure. Limits used in only
one center are 82–93, 85–97, 86–93, 86–94. 86–95, 86–96, 87–92, 88–
97, 89–92, 89–96, 90–92, 90–97, 90–98, 91–96, 92–94, 93–98, and 94–
99. Limits used in two centers are 83–93, 85–90, 86–92, 87–93, 87–95,
88–96, 89–94, and 95–96






























































Fig. 2 Former SpO2 ranges used in 156 European NICUs that changed
their limits in the last 10 years. Results are expressed as n (%). For clarity,
ranges reported by only one or two NICUs are not shown in the figure.
Limits used in only one center are 80–87, 84–92, 84–94, 84–96, 85–88,
86–96, 87–95, 88–97, 88–98, 89–95, 89–97, 90–96, 91–100, 92–95, 92–
97, 92–99, 93–97, 94–96, 94–98, 94–99, 95–98, 95–99, 92–97, 92–95,
90–100, and 91–100. Limits used in two centers are 80–95, 82–92, 85–
94, 86–95, 86–90, 86–93, 86–94, 87–92, and 90–97
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practice. It has been argued that, at present, the most rigorous-
ly evaluated evidence is that targeting a SpO2 of 91 to 95% is
safer than targeting a SpO2 of 85 to 89% [11, 15]. In 2013, a
European panel of experts, convened under the auspices of the
European Association of Perinatal Medicine to update
evidence-based guidelines on the management of neonatal
respiratory distress syndrome, recommended a saturation
range of 90–95% [13]. Our survey shows that this recommen-
dation is followed by only 28% of the respondent NICUs.
Moreover, the NeOProM higher target of 91–95% has been
adopted by only 5% of the NICUs. In general, the NICUs that
changed their range to 90–95 or 91–95% expect to obtain a
reduction in mortality and, to a lesser extent, a reduction in
neurodevelopmental impairment and NEC.
A number of neonatologists consider that the NeOProM up-
per limits may result in partial pressures of oxygen above the
physiologic limits given the characteristics of the hemoglobin
oxygen saturation curve [9, 10]. They suggest that it is safer to
widen the target, using SpO2 ranges like 86–93, 87–94, or 88–
94% [9, 10]. Our survey shows that these intermediate targets
are currently used by 14% of the respondent NICUs. It is note-
worthy that 45% of the NICUs that changed to intermediate
saturation targets also consider achieving a reduction in mortal-
ity probable or very probable. Finally, a 12% of the respondent
NICUs are using a wider SpO2 range of 88–95%. Their expec-
tations are similar than the ones reported by theNICUs using the
higher limits. Interestingly, independently of their choice of sat-
uration targets, more than 50% of the respondents consider the
evidence supporting their choice as strong or very strong.
In conclusion, a definitive answer to the optimal SpO2 level
for preterm neonates is still elusive. This is reflected in a wide
Table 3 Changes in SpO2 targeting limits introduced in European
NICUs in the last 10 years
Lower limit Upper limit
Increased Maintained Decreased
Increased n = 77 (40%) n = 28 (15%) n = 13 (7%)
L: 90 (85–92) L: 90 (85–92) L: 88 (86–94)
U: 95 (92–97) U: 95 (92–96) U: 95 (92–99)
Maintained n = 3 (2%) n = 37 (23%) n = 4 (2%)
L: 88 (85–88) L: 88 (83–93) L: 90 (88–90)
U: 95 (90–96) U: 95 (90–98) U: 95 (92–96)
Decreased 0 n = 1 (1%) n = 30 (16%)
L: 85 L: 88 (82–92)
U: 93 U: 94.5 (92–97)
n = number of centers (%). The number after L and U represents the
median (range) of the current SpO2 targeting limit. For example, 77 cen-
ters have increased both the lower and the upper SpO2 targeting limit in
the last 10 years. These 77 centers currently used a median lower limit of
90% (range 85–92) and a median upper limit of 95% (range 92–97)
L lower limit, U upper limit
Fig. 3 a–c Expected reduction in adverse outcomes after changes in
SpO2 ranges. The following question was posed: Which of the
following outcomes do you expect to be reduced with the new
saturation targeting policy? Participants were asked to respond through
a scale with 1 indicating very improbable and 5 indicating very probable.
For analysis of this question, responses were divided into three groups: a
NICUs using a lower limit of 86–88% and an upper limit ≤94% (n = 22),
b NICUs using a range of 88–95% (n = 19), and c NICUs using a lower
limit of 90–91% and an upper limit of 95% (n = 55). Neuro
neurodevelopmental impairment. d Opinion on the strength of scientific
evidence. The following question was posed: In your opinion, how strong
is the scientific evidence supporting the beneficial/harmful effects of the
oxygen saturation targeting policy that you are currently using in your
NICU for infants born at ≤28 weeks gestation? (scale with 1 indicating
very weak and 5 indicating very strong)
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variation of unit policies on SpO2 targets across Europe and
highlights the necessity of further investigation. Moreover,
since all five NeOProM trials used a similar study design, a
prospective meta-analysis is planned when follow-up of study
infants has occurred in the last trial [1]. Hopefully this meta-
analysis will help to find the best evidence-based SpO2
targets.
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